Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD’s Acreage Pharms Ltd. Receives Development Permit for Phase 2 and Provides Update

Invictus MD’s Acreage Pharms Ltd. Receives Development Permit for Phase 2 and Provides Update

 

FOREX INVESSTORS  PRESS RELEASE  Acreage Pharms Ltd   INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that its licensed production facility under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), Acreage Pharms Ltd. (“Acreage Pharms”) located near Edson, Alberta, utilizing a multi-room indoor perpetual growing methodology, will begin its first harvest the first week of August, with the second harvest occurring the following week.  The company anticipates a harvest to take place approximately monthly going forward.

Invictus MD is further pleased to announce that Acreage Pharms has received its development permit for Phase 2 and has broken ground initiating construction on its 27,800 square foot purpose built, multiple room production facility. All contractors and suppliers necessary for the project have been scheduled. Invictus MD has committed to investing $6.0 million, which will be used to fund the costs of constructing the production facility.

“Following our successful harvest at the AB Laboratories production facility as announced earlier, and by securing the development permit for our Alberta production facility, with $30 million cash available and the majority earmarked for building production capacity, Invictus MD is prepared for an exciting year of growth,” said Dan Kriznic, Executive Chairman and CEO, Invictus MD. “Led by one of the industry’s most experienced teams, we are strongly focused on building our shareholder value. With 250 acres of cultivation space that stretches from Alberta to Ontario, allowing for purpose built production facilities rather than retrofitting existing buildings, our large land package allows for building cultivation facilities as demand increases and we will continue the disciplined but agile execution of our business strategy, and further establishing our leadership position as Canada’s cannabis company” added Kriznic.



Acreage Pharms Ltd

Invictus MD also announced that Mr Paul Sparkes and Mr. Josef W. Hocher have been appointed to the Company’s Board of Directors.

Mr. Paul Sparkes is an accomplished business leader with over twenty five years’ experience in media, public affairs, venture capital, and Canada’s political arena. He is Currently President of Otterbury Holdings Inc., a corporation advising growth companies in the private and public markets.  Most recently Mr. Sparkes was Executive Vice Chair, Director and co-founder of Difference Capital Financial, a TSX-listed specialty finance company. Previously, Mr. Sparkes was Executive Vice President, Corporate Affairs for CTVglobemedia (now Bellmedia). Prior to joining Bell Globemedia in 2001 as Group Vice-President, Public Affairs, Mr. Sparkes held senior positions in public service, including with the Government of Canada and the Government of Newfoundland and Labrador. From 1996 to 2001, he served in the Office of the Prime Minister of Canada as Director of Operations, and Special Assistant for Atlantic Canada. Mr. Sparkes also served as Executive Assistant to two Premiers of Newfoundland and Labrador. Mr. Sparkes sits on several public and private boards including Thunderbird Entertainment (private), Bluedrop Performance Learning Inc. (TSXV: BPL), Antler Gold Inc (TSXV:ANTL.V) BlastGard International Inc (BLGA-US) and is a former board member of the Liquor Control Board of Ontario ( LCBO).

Mr. Josef W. Hocher was a founder of Buried Hill Energy, an international oil and gas company, where he acted as co-chief executive in creating, developing and implementing the organization’s strategic direction.  He continues to serve as the Senior Independent Director and is also either a Chair or a member of various committees. Mr. Hocher also founded Hitic Energy Ltd., and was a partner at Osler, Hoskin & Harcourt LLP. He currently serves as Chairman of Orthoshop Geomatics Ltd., a geomatics services company; holds the position of Chief Commercial Officer at Field Upgrading Limited and Western Hydrogen Limited and since 2016, has been a Partner at Cassels, Brock & Blackwell LLP.

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on two main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR, including its wholly owned subsidiary Acreage Pharms Ltd., as well as its investment in the fully licensed facility AB Laboratories Inc.; and Fertilizer and Nutrients through Future Harvest Development Ltd.

For more information, please visit www.invictus-md.com.

On Behalf of the Board,
Dan Kriznic
Executive Chairman & CEO

Larry Heinzlmeir
Vice President, Marketing & Communications
604-537-8676

Cautionary Note Regarding Forward-Looking Statements: Statements contained in this news release that are not historical facts are “forward-looking information” or “forward-looking statements” (collectively, “Forward-Looking Information”) within the meaning of applicable Canadian securities legislation and the United States Private Securities Litigation Reform Act of 1995. Forward Looking Information includes, but is not limited to, disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action; and the plans for completion of the Offering, expected use of proceeds and business objectives. In certain cases, Forward-Looking Information can be identified by the use of words and phrases such as “anticipates”, “expects”, “understanding”, “has agreed to” or variations of such words and phrases or statements that certain actions, events or results “would”, “occur” or “be achieved”. Although Invictus has attempted to identify important factors that could affect Invictus and may cause actual actions, events or results to differ materially from those described in Forward-Looking Information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended, including, without limitation, the risks and uncertainties related to the Offering not being completed in the event that the conditions precedent thereto are not satisfied. In making the forward-looking statements in this news release, Invictus has applied several material assumptions, including the assumptions that (1) the conditions precedent to completion of the Offering will be fulfilled so as to permit the Offering to be completed on or about June 1, 2017; (2) all necessary approvals will be obtained in a timely manner and on acceptable terms; and (3) general business and economic conditions will not change in a materially adverse manner. There can be no assurance that Forward-Looking Information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on Forward-Looking Information. Except as required by law, Invictus does not assume any obligation to release publicly any revisions to Forward-Looking Information contained in this news release to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD’s Executive Chairman Provides a Corporate Update

Invictus MD’s Executive Chairman Provides a Corporate Update

Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

BUZ INVESTORS  Corporate Update  INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) Canada’s Cannabis Company, is pleased to provide a corporate update on the back of its recently closed bought deal financing, and reprises its vision to expand and solidify its cultivation portfolio.

“Following our successful financing with Canaccord Genuity Corp., Eventus Capital Corp., Echelon Wealth Partners Inc., GMP Securities L.P. and PI Financial Corp., including the over-allotment option, for aggregate gross proceeds of $25,008,750, Invictus MD is well capitalized and prepared for an exciting year of growth,” said Dan Kriznic, Executive Chairman, Invictus MD. “Led by one of the industry’s most experienced teams, we are strongly focused on building our shareholder value. With 250 acres of cultivation space that stretches from Alberta to Ontario, allowing for purpose built production facilities rather than retrofitting existing buildings, we now have the largest land package in Canada for building cultivation facilities as demand increases and we will continue the disciplined but agile execution of our business strategy,” added Kriznic.

Corporate Update

“When its management team visited TSX Venture Exchange (TSXV) on May 5, 2017 and opened the trading day, we shared that celebration with all those who have contributed to our success – especially our team, the board, advisers and investors,” said Kriznic.  “From our early beginnings three years ago, we had a clear goal and the desire to do something remarkable within this budding marketplace.  We have always taken pride in knowing we’re working towards becoming a source of uncompromising quality of medical cannabis and to be ready for the future new recreational market upon legalization.”

In early May, AB Ventures Inc. (“AB Ventures”), an incorporated company formed to develop a second licensed expansion facility through its common ownership with AB Laboratories Inc. (“AB Labs”) a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) which maintains a 16,000 square foot facility located near Hamilton, Ontario, closed its 100-acre land acquisition and once licensed under the ACMPR, will be used for future cannabis cultivation.  To facilitate the construction of the initial 42,000 square foot cultivation facilities, with plans to construct additional production facilities on the new land totaling 100,000 square feet, Mr. Michael Alezane has been appointed construction manager.  Considering the magnitude of AB Ventures’ land holdings and future production facilities, and assuming AB Ventures obtains a license to produce the quantity forecasted for the proposed facility, we will have the capacity for significant growth to keep pace with the growing medical and future recreational demand.

AB Labs, which has achieved full production capacity, recently conducted its first harvest with very favorable results and will shortly apply for its pre-sales inspection.

“The Company is focused on achieving increased production profile growth in the near future.  Cultivation began earlier in the month at Acreage Pharms Ltd. (Acreage Pharms), a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”),” stated Trevor Dixon, President and CEO of Invictus MD. “Planning has begun for the Phase 2 build out; Acreage Pharms has an existing 6,800 square foot production facility with an expansion plan floor plate of 27,400 square feet, that sits on 150 acres of land in West Central Alberta. To facilitate the construction of Phase 2, Mr. Harmen Bangma has been appointed construction manager.” Alberta has low cost of production as a result of low energy and water costs and provides the capability to construct facilities to meet the demand that the coming adult recreational marijuana use will create. Acreage Pharms also has plans to produce extracted or oil based products oils are rapidly gaining market share in the marijuana sector.

Invictus MD’s wholly owned venture into consumer cannabis devices; Poda Technologies Ltd. (“Poda”), is set imminently for a spin out.

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp., Canada’s Cannabis Company, is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR including investment in the fully licensed facilities operated by AB Laboratories Inc. and Acreage Pharms Ltd.; Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.

For more information, please visit www.invictus-md.com.

Business Description

Industry: Asset Management » Asset Management    NAICS: 523999    SIC: 7299
Compare: OTCPK:(HGBL), OTCPK:(WISH), OTCPK:(PRDGF), OTCPK:(AABVF), AMEX:(RCG), NAS:(RAND), OTCPK:(GRNBF), AMEX:(NPN), OTCPK:(LDHL), AMEX:(MIW), OTCPK:(INNO), NAS:(XRDC), NAS:(GROW), OTCPK:(HALN), AMEX:(NJV), AMEX:(MAB), OTCPK:(HGHRF), AMEX:(EMI), NYSE:(MTR), AMEX:(GRF) » details
Traded in other countries: IMH.Canada, 8IS1.Germany,
Headquarter Location: Canada

Invictus MD Strategies Corp is engaged in the investment, acquisition and development of synergistic businesses in an effort to increase and sustain growth and value.

 

 

Like up on FACEBOOK

 


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )

Buz Investors Canopy Growth Added to S&P/TSX - Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or "the Company") today announced that by being added to the S&P/TSX Composite Index,

Canopy Growth Corporation Enters Into An Agreement with Invictus MD’s AB Laboratories For Cannabis Sales

Canopy Growth Corporation Enters Into An Agreement with Invictus MD’s AB Laboratories For Cannabis Sales

 

BUZ INVESTORS Canopy Growth Corporation INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") (TSXV: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that AB Laboratories Inc.

BUZ INVESTORS  Canopy Growth Corporation  INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that AB Laboratories Inc. (“AB Labs”), a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), will provide their unique products in Canopy Growth Corporation’s (TSX:WEED) (“Canopy Growth”) curated CraftGrow line on Tweed Main Street’s online store, that brings high quality cannabis grown by a diverse set of producers. People want variety, they want different choices, and Tweed Main Street is an opportunity in the legal market where patients can see what is available through the convenience of an online store.

“AB Labs has received a number of direct inquiries from patients, which underscores the continuously growing demand. As a newer licensed producer with a market capitalization less than our peers, we are able to utilize Canopy Growth’s Tweed Main Street, giving us immediate access to the largest customer base in the rapidly expanding medical cannabis market.” said Dan Kriznic, Chairman and CEO of Invictus MD.  “Our collaboration with Canopy Growth demonstrates our commitment to making the sector strong and helping to expose medical cannabis patients visiting Tweed Main Street, to another high quality, unique brand.”




Canopy Growth Corporation

With Canada on the global stage as it moves closer to making history by being the first G-7 nation to legalize and regulate access to cannabis for the recreational market and the expected demand that will result, Invictus MD will continue to focus on building out AB Labs and AB Ventures Inc.’s (“AB Ventures”) production capacity in Ontario and successfully acquiring Acreage Pharms Ltd.’s (“Acreage Pharms”) production facility in Alberta.  After the successful development and acquisition of these facilities, Invictus MD anticipates that it will have the capacity to supply more than 50,000 kg of cannabis by 2020. This creates an attractive value proposition in the burgeoning cannabis market.

AB Labs, which maintains a 16,000 square foot facility located near Hamilton, Ontario, has successfully conducted test crops and is currently operating at half capacity, with full production capacity scheduled by the end of May 2017.  AB Ventures Inc.’s (“AB Ventures”), a company formed to develop a second licensed expansion facility through it’s common ownership with AB Labs, is expected to close a 100-acre acquisition on May 1, 2017, and if licensed under the ACMPR, construction of production facilities totaling 250,000 square feet will begin and be used for future cannabis cultivation. With licensing in place as expected, production at AB Ventures is anticipated to start as early as December 2017.

Considering the magnitude of AB Ventures’ land acquisition and future production facilities, and assuming AB Ventures obtains a license to produce the quantity forecasted, Invictus MD anticipates the combined production capacity of both AB Labs and AB Ventures to exceed 25,000 kilograms in 2020.

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR including an investment in a fully licensed facility, AB Laboratories Inc. as well as the option to now acquire 100% of Acreage Pharms Ltd.; Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd
.

Like up on FACEBOOK


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD’s Future Harvest Achieves Increase In Gross Margin Benefiting From Its Focus On The Burgeoning Global Cannabis Sector

Invictus MD’s Future Harvest Achieves Increase In Gross Margin Benefiting From Its Focus On The Burgeoning Global Cannabis Sector

 

 

 Invictus MD’s Future Harvest Achieves Increase

BUZ INVESTORS Invictus MD's Future Harvest Achieves Increase INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") (TSXV: IMH; OTC: IVITF; FRA: 8IS) is pleased to report that Future Harvest Development

 BUZ INVESTORS  Invictus MD’s Future Harvest Achieves Increase  INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) is pleased to report that Future Harvest Development Ltd. (“Future Harvest”), of which Invictus MD currently owns 82.5%, has generated $1.787 million in revenue for the 9 months ending March 31, 2017, with a gross margin of $907,864, representing a 50.8% gross margin compared to the same period in the prior year gross margin of $642,773, and a 35.9% margin.

Chris Pearson, Chief Revenue Officer of Future Harvest commented that, “we supply specialty fertilizers and other supplies for hydroponics, the indoor method of growing crops favored by cannabis cultivators.  We know there’s a massive market out there; we’re directly focused on what’s made our business successful: high-value crops. To seize the growing demands in the cannabis sector, we’ve ramped up production by installing a second, fully automated bottling line increasing overall production efficiency by 400%, and a state-of-the-art pill press (patent pending), enabling us to produce water-soluble nutrient tablets, eliminating the need for water and salt and greatly reducing packaging and transportation costs for large-scale commercial applications. These initiatives further position us for the highly profitable business opportunities within the global cannabis sector.”



OTHER STORIES BUZ TRADERS FOLLOW

 Invictus MD’s Future Harvest Achieves Increase

Dan Kriznic, Chairman and CEO of Invictus MD commented, “Future Harvest’s success reinforces our focused execution on being a leader in the burgeoning global cannabis industry as Canada moves closer to legalized recreational marijuana. We remain confident in our ability to delivering strong results this year, and expand Future Harvest’s ability to further increase our shareholder value.”

About Future Harvest Development Ltd.

For over twenty years, Future Harvest has brought fertilizers, metering and monitoring equipment and other supplies for hydroponics, the indoor method of growing crops favored by the burgeoning cannabis industry,

Future Harvest’s product lines are available through leading distributors and retailers across North America, the United Kingdom and Europe and include Nutradip, Plantlife Products and Future Harvest Plastics.

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR including an investment in a fully licensed facility, AB Laboratories Inc. as well as the option to now acquire 100% of Acreage Pharms Ltd.; Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.

Like up on FACEBOOK


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD’s Acreage Pharms Begins Cultivation with Commitment to Produce High Quality Cannabis

Invictus MD’s Acreage Pharms Begins Cultivation with Commitment to Produce High Quality Cannabis

 

BUZ INVESTORS Invictus MD’s Acreage Pharms Begins Cultivation INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") (TSXV: IMH; OTC: IVITF; FRA: 8IS) announces that Acreage Pharms Ltd. ("Acreage Pharms") which Invictus MD has the option to now acquire

BUZ INVESTORS Invictus MD’s Acreage Pharms Begins Cultivation   INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) announces that Acreage Pharms Ltd. (“Acreage Pharms”) which Invictus MD has the option to now acquire 100 percent and expect to exercise in short order, begins their new cultivation cycle, having received their license to cultivate under the Access to Cannabis for Medical Purposes Regulations (“ACMPR“), they are firmly committed to patient safety and the quality of their cannabis.

“Since being founded, we have established and emphasized a strict culture of regulatory compliance and have committed to enforcing a rigorous Quality Management Program and closely monitoring all our suppliers to ensure that any products used meet or exceed the minimum standards set to comply with Health Canada’s regulations,” said Trevor Dixon, Founder and CEO of Acreage Pharms.  “Our best-in-class Quality Assurance and testing protocols, will give our future clients additional certainty regarding the purity and safety of the medical cannabis we produce. When we set out on this exciting new endeavour we planned on achieving the highest standards when it came to the cultivation and production of medical cannabis. As part of this, we made an important investment in our state-of-the-art, purpose built growth facility near Edson, Alberta, that enables us to produce medical cannabis that meets our exacting standards of quality, consistency, and safety.”



OTHER STORIES BUZ TRADERS FOLLOW

Invictus MD’s Acreage Pharms Begins Cultivation

Dixon further stated, “additionally, to ensure product integrity through every step of the growing process, we will utilize fertilizer from Future Harvest Development Ltd. (“Future Harvest”), of which Invictus MD currently owns 82.5%, which significantly reduces the risk of unwanted chemicals that might be found in other fertilizers.” Chris Pearson, Chief Revenue Officer of Future Harvest commented that, “We’re committed to our customers’ quality outcomes.  At Future Harvest we’re highly dedicated to consistently producing the highest quality nutrient formulations. This is achieved through our Standard Operating Procedures including closely monitoring and having regular detailed dialogues with our global supply partners to ensure product consistency, a five times cleaning protocol for all batch and formulation tanks, and an independent detailed analysis sample procedure.”

“We’re very proud that Acreage Pharm’s management team has taken steps to implement quality assurance practices and operational controls at the very beginning in order to ensure operations are at a world class standard level,” stated Dan Kriznic, Chairman and CEO of Invictus MD.  “We’re all steadfast in out commitment to lead with practices that meet or exceed the regulatory standard for safety and quality in the Canadian cannabis industry.  We are Canada’s Cannabis Company™.”

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR including an investment in a fully licensed facility, AB Laboratories Inc. as well as the option to now acquire 100% of Acreage Pharms Ltd.; Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.

For more information, please visit www.invictus-md.com.

Like up on FACEBOOK


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD’s Chairman Provides March in Review

Invictus MD’s Chairman Provides March in Review

 

BUZ INVESTORS Invictus MD's Chairman - INVICTUS MD STRATEGIES CORP. <span data-recalc-dims=(TSXV:IMH) ("Invictus MD" or the "Company"), Canada's Cannabis Company, is pleased to provide a month in review." width="300" height="195" srcset="https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/03/InvictusLogo.jpg?resize=300%2C195 300w, https://i2.wp.com/investorsbuz.com/wp-content/uploads/2017/03/InvictusLogo.jpg?w=743 743w" sizes="(max-width: 300px) 100vw, 300px" />

BUZ  INVESTORS Invictus MD’s Chairman  – INVICTUS MD STRATEGIES CORP. (TSXV:IMH) (“Invictus MD” or the “Company”), Canada’s Cannabis Company, is pleased to provide a month in review.

March was a transformational time for Invictus MD as it worked to expand and solidify its cultivation portfolio with expansion plan forecasts of 50,000 kilograms of high quality cannabis production by 2020.

CBC News learned that marijuana could be legal in Canada by July 1, 2018 and that the legislation will be announced during the week of April 10, and will broadly follow the recommendation of a federally appointed task force that was chaired by former liberal Justice Minister Anne McLellan. CBC News further reported that the federal government would be in charge of making sure the country’s marijuana supply is safe and secure, and Ottawa will license producers.




 

OTHER STORIES BUZ TRADERS FOLLOW

Invictus MD’s Chairman

It’s reported that Canada’s cannabis industry could reach $22.6 billion over the coming years, according to Deloitte, with a retail market worth up to $8.7 billion. With only 41 producers licensed by Health Canada thus far, there’s a significant market opportunity for Invictus MD to capitalize on this growth over time. The Company has focused on building its production profile and during March, many significant milestones were achieved. Some of those highlights are as follows:

  • On March 2nd the company announced that it had closed its previously announced bought deal private placement with Canaccord Genuity Corp. and Eventus Capital Corp., including a portion of the over-allotment option, for aggregate gross proceeds of $16,218,065. A total of 9,829,130 units, including those pursuant to the exercise of the over-allotment option, were issued at a price of $1.65 per Unit.
  • On March 14th the Company completed its final commitment with a cash transaction of CAD$2,000,000 to acquire 33.33% of AB Laboratories Inc. (“AB Labs”), a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) which maintains a 16,000 square foot facility located in Hamilton, Ontario. Invictus MD has the right of first refusal to arrange any initial public offering, reverse take-over or other going public transaction of AB Labs.
  • AB Labs had successfully conducted test crops and is currently operating at half capacity, with full production capacity scheduled by the end of May 2017. They have also acquired a number of different strains and are negotiating numerous others for R & D purposes. AB Labs has already received a number of direct inquiries from patients, which underscores the continuously growing demand.
  • AB Ventures Inc.’s (“AB Ventures”), a newly incorporated company formed to develop a second licensed expansion facility through it’s common ownership with AB Labs, 100-acre acquisition is scheduled to close on May 1, 2017, and once licensed under the ACMPR, will be used for future cannabis cultivation. Invictus MD made a commitment to invest $5.5 million, which was in addition to the $2 million already funded for the land acquisition plus working capital, and will provide Invictus MD with a 33.33% interest in AB Ventures. Funds will be used for the costs of licensing approval under the ACMPR, and constructing the initial 42,000 square foot cultivation facilities, with plans to construct an additional five production facilities on the new land totalling 100,000 square feet. In preparation for a fully compliant application, AB Ventures will be using AB Labs respective persons in charge that have already been cleared by Health Canada, reducing the amount of time to get a secondary license, as security clearance is a lengthy process under the ACMPR approval process. With licensing in place as expected, production at AB Ventures is anticipated to start as early as December 2017.
  • Considering the magnitude of AB Ventures’ land acquisition and future production facilities, and assuming AB Ventures obtains a license to produce the quantity forecasted for the proposed facility, the combined production capacity of both AB Labs and AB Ventures is expected to exceed 25,000 kilograms in 2020.
  • Invictus MD closed the definitive option agreement to acquire 100% interest in OptionCo., and on March 30, 2017 announced that OptionCo had received its license to cultivate under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) as Acreage Pharms Ltd. (“Acreage Pharms”), who has constructed a 6,800 square foot production facility with an expansion plan floor plate of 30,000 square feet, and the option to add a 20,000 square foot mezzanine that sits on 150 acres of land in Edson, Alberta. Alberta has low cost of production as a result of low energy and water costs. This large land package of up to 3 million square feet of buildable property has a footprint larger than 60 football fields, and provides the capability to construct facilities to meet the demand that the coming adult recreational marijuana use will create. Acreage Pharms also has plans to produce extracted or oil based products oils are rapidly gaining market share in the marijuana sector. By 2020 Acreage Pharms anticipates production to exceed 25,000 kilograms of high quality, low cost cannabis.
  • On March 30, 2017 Invictus MD, Canada’s Cannabis Company, announced that its common shares would be listed on the TSX Venture Exchange (“TSXV”) commencing at the open of trading on March 31, 2017; the Company’s trading symbol “IMH” will remain the same. Invictus MD’s move from the CSE to the TSXV follows a year of significant achievements.

“As one of the few cannabis producing companies in North America listed on a major exchange such as the TSXV, that move will enable us to engage a wider investor audience,” said Dan Kriznic, Chairman & CEO, Invictus MD. “We are strongly focused on building our shareholder value. With 250 acres of cultivation space that stretches from Alberta to Ontario, allowing for purpose built production facilities rather than retrofitting existing buildings, we now have the largest land package in Canada for building cultivation facilities as demand increases and we will continue the disciplined but agile execution of our business strategy,” added Kriznic.

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR including an investment in a fully licensed facility, AB Laboratories Inc. as well as the option to now acquire 100% of Acreage Pharms Ltd.; Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )